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Herpes simplex virus (HSV)-1 and HSV-2 are signifi-
cant human pathogens causing recurrent disease.
During infection, HSVmodulates cell death pathways
using the large subunit (R1) of ribonucleotide reduc-
tase (RR) to suppress apoptosis by binding to
and blocking caspase-8. Here, we demonstrate that
HSV-1 and HSV-2 R1 proteins (ICP6 and ICP10,
respectively) also prevent necroptosis in human cells
by inhibiting the interaction between receptor-inter-
acting protein kinase 1 (RIP1) and RIP3, a key step
in tumor necrosis factor (TNF)-induced necroptosis.
We show that suppression of this cell death pathway
requires an N-terminal RIP homotypic interaction
motif (RHIM) within R1, acting in concert with the
caspase-8-binding domain, which unleashes nec-
roptosis independent of RHIM function. Thus, nec-
roptosis is a human host defense pathway against
two important viral pathogens that naturally subvert
multiple death pathways via a single evolutionarily
conserved gene product.
INTRODUCTION
Programmed cell death (PCD) is an important form of cell-auton-
omous immune control over intracellular pathogens. Virus-
encoded suppressors prevent premature cell death that would
otherwise stop infection (Mocarski et al., 2012; Upton and
Chan, 2014). Host adaptation of necroptosis arose as a trap
door to eliminate pathogens that block caspase-8 (Casp8) (Kai-
ser et al., 2013b). Vaccinia and reovirus show susceptibility to
necroptosis in mouse cells (Berger and Danthi, 2013; Chan
et al., 2003; Cho et al., 2009). In contrast, murine cytomegalo-
virus (MCMV) M45-encoded viral inhibitor of RIP activation
(vIRA) blocks necroptosis by disrupting receptor-interacting pro-
tein kinase (RIP) homotypic interaction motif (RHIM) signal trans-
duction in mouse cells and mice (Upton et al., 2008, 2010, 2012).
vIRA naturally prevents DNA activator of interferon (DAI) RHIM-
dependent recruitment of RIP3 (Upton et al., 2010, 2012) andCell Host &consequent phosphorylation of mixed-lineage kinase domain-
like (MLKL) that results in cell death (Kaiser et al., 2013a). M45
also carries out RHIM-independent activities (Fliss et al., 2012;
Krause et al., 2014) mediated by a domain that bears homology
to the large subunit (R1) of ribonucleotide reductase (RR) (Lembo
and Brune, 2009). Importantly, M45 mutant viruses fail to infect
mice (Brune et al., 2001; Lembo et al., 2004) due to induction
of unleashed necroptosis (Upton et al., 2010, 2012).
Independent of viral infection, M45-encoded vIRA blocks
all RHIM-signaling pathways, including TNF death receptor 1
(TNFR1)-dependent RIP1-RIP3 necroptosis (Upton et al., 2010)
as well as Toll-like receptor 3 (TLR3) and TLR4-dependent TIR-
domain-containing adaptor-inducing interferon-b (TRIF)-RIP3
necroptosis (Kaiser et al., 2013a). As a competitor of RIP3
RHIM signaling (Kaiser et al., 2013b;Mocarski et al., 2014; Upton
and Chan, 2014), vIRA prevents formation of a RIP1-RIP3 ne-
crosome (Upton and Chan, 2014; Vandenabeele et al., 2010) or
TRIF-RIP3 or DAI-RIP3 complexes (Kaiser et al., 2013a) and
the consequent phosphorylation of MLKL that commits cells to
death (Sun et al., 2012; Zhao et al., 2012). vIRA also blocks the
RHIM-dependent signaling step involved in RIP3-initiated
apoptosis (Kaiser et al., 2014; Mandal et al., 2014; Newton
et al., 2014), involving the ripoptosome (Feoktistova et al.,
2011). This complex is now recognized to include RIP3 and
RIP1 together with the long form of FLICE inhibitory protein
(FLIPL), Fas-associated protein with death domain (FADD), and
Casp8 (Kaiser et al., 2014; Mandal et al., 2014).
Herpes simplex virus 1 (HSV-1) and HSV-2 regulate PCD dur-
ing infection (Galvan and Roizman, 1998; Leopardi et al., 1997).
Both TNFR1- and TLR3-mediated innate immunity contribute to
host defense against HSV (Bousfiha et al., 2010; Lundberg et al.,
2007; Sergerie et al., 2007; Zhang et al., 2013). In addition
to catalyzing production of deoxyribonucleotides (Goldstein
and Weller, 1988), HSV-1 ICP6 and HSV-2 ICP10 block Casp8-
dependent apoptosis (Chabaud et al., 2007), mediated by RR
domain binding to the Casp8 death effector domain (Dufour
et al., 2011b) in a pattern suggests R1 acts like a viral FLIP or a
betaherpesvirus-encoded inhibitor of caspase activation (vICA)
to compromise caspase enzymatic activity (McCormick and
Mocarski, 2013; Mocarski et al., 2012).
Here, HSV-1 and HSV-2 R1 proteins are shown to prevent
death receptor-induced necroptosis in virus-infected human
cells by disrupting RHIM-dependent interactions between RIP1Microbe 17, 243–251, February 11, 2015 ª2015 Elsevier Inc. 243
Figure 1. Role of HSV R1 in Suppression of Virus-Induced Death
(A) Viability of HSV-1 strain KOS or DICP6 mutant virus-infected HT-29 cells (MOI = 5), or mock-infected, and treated from 2 to 24 hpi with TNF (T; 30 ng/ml), IAP
antagonist BV6 (S; 1 mM), and/or caspase inhibitor zVAD (V; 25 mM) alone or in the combinations shown. Viability was determined by measuring ATP levels. Data
are normalized to DMSO solvent control (% untreated cells).
(B) IB to detect cleaved Casp3 (Cl-Casp3), phosphorylated MLKL (p-MLKL), and b-actin in HT-29 cells infected with KOS or DICP6 (MOI = 5), or mock-infected,
and then treated with T, T+S, T+V, T+S+V, or DMSO solvent control () from 2 to either 10 or 15 hpi, as indicated.
(C) Replication levels of KOS (left) and DICP6 (right) virus in HT-29 cells (MOI = 5) in DMSO control medium or in medium containing T + IAP antagonist SMAC007
(S7, 1 mM) (Mandal et al., 2014), T+S7+V, or T+S7+Vwith RIP1 kinase inhibitor GSK’963 (1 mM) or RIP3 kinase inhibitor GSK’840 (3 mM), as shown. Viral titers were
determined by plaque assay on Vero cells at the indicated time (hpi).
(D) IB to detect viral antigens and b-actin following infection of HT-29 cells with KOS or DICP6 virus (MOI = 5) in the presence of phosphonoformate (300 mg/ml)
and then either left untreated or treated with T+S+V from 2 to 4 or 8 hpi.
(legend continued on next page)
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andRIP3. The C-terminal Casp8-binding RR domain suppresses
apoptosis and suffices to unleash necroptosis. Thus, in addition
to disrupting Casp8 signaling, HSV R1 simultaneously activates
and blocks the pro-necrotic trap door.
RESULTS
HSV R1 Suppresses Necroptosis
We initially focused on the ability of HSV-1 ICP6 to inhibit TNFR1-
dependent PCD in human HT-29 adenocarcinoma cells. These
cells support necroptosis as well as apoptosis (He et al., 2009)
andare also susceptible toHSV-1 infection (Figure 1). HT-29 cells
infected (MOI = 5) with either WT HSV-1 (KOS) or DICP6 mutant
virus remained viable; however, treatment with TNF (T) alone
from 2 to 24 hpi significantly reduced viability of DICP6 virus-
infected cells (Figure 1A). Immunoblot (IB) analysis revealed
markers of apoptosis (cleaved Casp3) and necroptosis (phos-
phorylation of the RIP3 substrate MLKL) (Figure 1B). Susceptibil-
ity of DICP6-infected cells increased dramatically when the
IAP antagonist BV6 (S) was added (Varfolomeev et al., 2007),
whereas mock-infected cells showed an expected (He et al.,
2009) modest increase. Addition of pan-caspase inhibitor
zVAD-fmk (V) did not rescue DICP6- or mock-infected cells (Fig-
ure 1A), but switched PCD to necroptosis (phosphorylation of
MLKL by 10 hpi; Figure 1B). T+S+V induced maximal levels of
MLKL phosphorylation in DICP6-infected cells. Mock-infected
cells behaved as expected (He et al., 2009), and parental KOS-
infected cells resisted treatment (Figure 1A), demonstrating that
HT-29 cells became sensitized to TNFR1-mediated PCD in the
absence of R1. Treatment from 2 to 14 hpi with either T or anti-
Fas antibody (F) alone sufficed to induce DICP6-infected cell
death (Figure S1A), although F+Sor F+S+V resulted in less death.
Inclusion of IAP antagonist had a greater impact onTNFR1-medi-
ated death. To further distinguish death pathways that play
out under these conditions, RIP1 kinase inhibitor GSK’963
(Weng et al., 2014) and RIP3 kinase inhibitor GSK’840 (Mandal
et al., 2014) were shown to reverse death of DICP6-infected cells
following T+V treatment, particularly in the presence of IAP
antagonist SMAC007 (S7; Figure S1B). KOS-infected cells re-
mained viable when viral DNA synthesis was blocked using
phosphonoformate (Figure S1C), indicating early gene confers
resistance to cell death. In summary, HSV-1 R1 mutant virus
sensitized cells to TNFR1- or Fas-mediated death pathways
that are blocked when ICP6 is made early after infection.
To compare KOS and DICP6 virus replication, we performed
one-step growth curves (MOI = 5) with viral stocks produced
on cells expressing N-terminal FLAG-tagged ICP6 (HT-29-
ICP6). These cells fully complement replication of DICP6 to WT
levels. On non-complementing HT-29 cells, DICP6 and KOS
replication was comparable through 12 hpi, when titers were
4.3 and 4.7 log10 pfu/ml, respectively (Figure 1C). Consistent
with previous data showing that viral RR activity is required to
sustain replication (Goldstein and Weller, 1988), titers of DICP6(E) Viability of HT-29 cells stably expressing nontargeted (Sc) shRNA or MLKL-
treated with T, T+S, T+V, or T+S+V for 24 hr.
(F) Replication levels of KOS (left) and DICP6 (right) virus in HT-29 cells (MOI = 5
control) or presence of T+S7 or T+S7+V as shown. Data with error bars depict me
0.001 indicated above bars. See also Figure S1.
Cell Host &only increased modestly between 12 and 24 hpi (Figure 1C). Un-
der multiple-step growth conditions, DICP6 exhibited a more
dramatic replication defect than KOS (Figures S1D–S1F). Impor-
tantly, T+S7 or T+S7+V had a greater impact on DICP6 virus
titers (Figure 1C), and the impact of T+S7+V was rescued by
the addition of RIP1 or RIP3 kinase inhibitor. To compare accu-
mulation of early viral proteins, we performed an IB analysis on
infected cells (MOI = 5) and found the same pattern of viral anti-
gen accumulation in both viruses through 8 hpi, in the presence
or absence of phosphonoformate, as well as with or without
T+S+V treatment (Figure 1D and data not shown). Consistent
with markers of cell death (Figure 1B), DICP6-infected (MOI =
5) MLKL knockdown cells resisted necroptosis induced by
T+S+V (or T+S7+V) but were sensitive to apoptosis induced by
T or T+S, like control cells (Figure 1E and data not shown).
Furthermore, T+S7+V treatment reduced levels of DICP6 virus
replication in control cells but not in MLKL knockdown cells,
whereas yields of KOS remained unaffected (Figure 1F). Given
that HSV-1 could impact TNFR1-dependent death signaling
by reducing levels of cIAP1, cIAP2, or cFLIPL (Dufour et al.,
2011a), we evaluated all three proteins in DICP6- and KOS-in-
fected cells. cFLIPL levels were lower by 6 hpi independent of
R1 expression, but cIAPs remained stable (Figure S1G). Thus,
differences did not arise from modulation of these proteins.
HSV R1 Is Sufficient to Protect Human Cells from
Necroptosis
The experiments above revealed a requirement for HSV-1 R1
to suppress sensitivity to necroptosis during virus infection. In
order to assess R1 function independent of virus infection, HT-
29-ICP6 cells, as well as empty vector (EV) and FLAG-tagged
HSV-2 ICP10 (called HT-29-EV and HT-29-ICP10, respectively),
were treated with T+S+V. HT-29-ICP6 and HT-29-ICP10 cells
remained impermeable to SYTOX Green uptake and viable,
in stark contrast to the pattern of necroptosis in HT-29-EV cells
(Figures 2A, 2B, and S2A). Similar levels of protection were
observed with MCMV-encoded M45 (Figure S2B), revealing
a common ability of R1 homologs from HSV-1, HSV-2, and
MCMV to block necroptosis in human cells. Like KOS-infected
cells (Figure S1A), ICP6- or ICP10-expressing HT-29 cells re-
sisted Fas-induced necroptosis (F+S+V; Figure S2C). Cell death
suppression by ICP10 was maintained through 48 hr post-treat-
ment, indicating a block rather than a delay in death (Figure S2D).
ICP10 also protected necroptosis-sensitive human U937 cells
treated with T alone, T+S, T+V, or T+S+V (Figure S2E), revealing
activity in a second human cell line. Given that MCMV M45 is
active in human cells, we evaluated ICP6 and ICP10 in a necrop-
tosis-sensitive 3T3-SA mouse cell line; however, HSV-2 ICP10
only modestly protected against T+V, and HSV-1 ICP6 modestly
increased death of cells treated with V or T+V (Figures S2F and
S2G), in contrast to M45 (Figure S2H). The ICP6 result aligns
with recent reports of RHIM-dependent activation of necroptosis
in mouse fibroblasts (Huang et al., 2015; Wang et al., 2014) andspecific shRNA either mock-infected (left) or DICP6-infected (right) and then
) stably expressing either Sc shRNA or MLKL shRNA in the absence (DMSO
an ± standard deviation (SD); with significance *p < 0.05, **p < 0.01, and ***p <
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Figure 2. HSV R1 Inhibits TNF-Induced Necroptosis by Competing for RHIM-Dependent Interaction of RIP1 and RIP3
(A) Time course depiction of the accumulation of SYTOX Green-permeable HT-29-EV, HT-29-ICP6, or HT-29-ICP10 cells (images shown in Figure S2A).
(B) Viability of HT-29-EV, HT-29-ICP6, or HT-29-ICP10 cells treated for 24 hr with T, S, V, or the combinations indicated.
(C) IB for RIP3, RIP1, phospho-RIP1-S166, and b-actin in cell lysates from HT-29-EV and HT-29-ICP10 cells treated for the indicated times with T+S+V. An
asterisk marks slower-migrating modified forms of RIP3 or RIP1.
(D) IP/IB to detect RIP1 interaction with RIP3 in HT-29-EV and HT-29-ICP10 cells. Top panels show IP of cell lysates with anti-RIP1 antibody followed by IB with
anti-RIP3 or anti-RIP1 antibody. Middle panels show endogenous RIP3 and RIP1, as well as transduced FLAG-ICP10, in clarified lysates. Bottom panels show
RIP3 and RIP1 in the pellet fraction. The vertical line shows where lanes from the original gel were brought adjacent.
(E) IP/IB to detect ICP6 interaction with RIP kinases. Top panels show lysates of 293T cells transfected with FLAG-ICP6 andMyc-tagged humanRIP1, RIP2, RIP3,
or RIP4 subjected to IP with anti-Myc antibody followed by IB with anti-FLAG or anti-Myc antibody.
(F) IP/IB to detect ICP6 interaction with WT and mutant forms of RIP1. Top panels show lysates of cells transfected with Myc-ICP6 and FLAG-tagged versions of
RIP1, RIP1(301–558), RIP1(301–558, mutRHIM), RIP3, or RIP3mutRHIM subjected to IP with anti-FLAG antibody followed by IB with anti-Myc or anti-FLAG
antibody.
(G) IP/IB demonstrating ICP10 disruption of RIP1 and RIP3 interaction. Top panels show lysates of cells transfected with FLAG-RIP3 with or without Myc-RIP1 in
the presence of 0, 0.2, 0.5, or 1.0 mg FLAG-ICP10 subjected to IP with anti-Myc antibody followed by IB with anti-FLAG or anti-Myc antibody. The lower panels
depict IB of input cell lysates. Protein molecular size is shown to the right of the lanes. Data with error bars depict mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S2.
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indicates that ICP6 and ICP10 suppressor activity may be
restricted to the natural host species for HSV.
HSV R1 RHIM-Dependent Suppression of RIP1-RIP3
Interaction
To investigate the impact of R1 on RIP kinases during TNFR1-
mediated necroptosis, HT-29-EV and HT-29-ICP10 cell extracts
were collected at 2 hr intervals for IB analysis following T+S+V
treatment. ICP10 completely suppressed the modification and
reduced levels of both RIP1 and RIP3 that accumulated in HT-
29-EV extracts by 4 hr (Figure 2C). ICP10 also delayed the
appearance of a specific phospho-S166 form of RIP1 by 2 hr,
suggesting that RIP1 kinase activity was compromised. Immu-
noprecipitation (IP) with RIP1-specific antibody at 2 or 4 hr re-
vealed disruption of the RIP1-RIP3 interaction by ICP10 as well
as failure to redistribute into the pellet fraction (Figure 2D).
Thus, HSV R1 apparently prevents necrosome formation.
We next evaluated the FLAG epitope-tagged ICP6 or ICP10
interaction with RIP kinases in 293T cells transfected with Myc
epitope-tagged versions of RIP1, RIP2, RIP3, or RIP4. R1 inter-
acted with RHIM-containing kinases RIP1 and RIP3, but not
with either RIP2 or RIP4 (Figures 2E and S2I–S2K). FLAG-tagged
RIP1 intermediate domain (301–558 aa), containing the RHIMbut
lacking both the kinase domain and death domain, retained
the ability to bind either Myc-tagged R1 (Figure 2F and S2J).
The interaction of RIP1 or RIP3 with ICP6 or ICP10 was ablated
by mutation of the RHIM (Figures 2F, S2L, and S2M). Impor-
tantly, increasing amounts of ICP10 disrupted RIP3-RIP1 inter-
action (Figure 2G). Thus, HSV R1 disrupts the RHIM-dependent
interaction of RIP1 and RIP3 to prevent necrosome formation.
Both the RHIM and RR Domain of R1 Are Essential for
Death Suppression
We next investigated the contribution of putative RHIM-like ele-
ments upstream of the R1 domain of epitope-tagged versions of
HSV-1 ICP6 and HSV-2 ICP10, with a cysteine at a core position
where all other bona fide RHIM proteins have an isoleucine,
leucine, or valine (Figure 3A). Although levels of ICP6mutRHIM
and ICP6(D1–243) mutants were similar to WT in transduced
HT-29 cells (Figure S3A), neither protected mock- or DICP6-in-
fected cells from T+S+V (Figure 3B). ICP6 mutants eliminating
portions of the RR domain were expressed, but only ICP6(1–
1116) protected, and less well than full-length ICP6. ICP6(1–
1106) or shorter mutants did not protect at all (Figure 3C).
Despite an inability to block death, ICP6(1–629) retained the abil-
ity to interact with human RIP1 or RIP3 in transfected 293T cells,
consistent with the retention of a RHIM (Figure 3D). These data
strongly implicate the R1 RHIM in controlling RIP1 and RIP3 in-
teractions to prevent necroptosis. Even though the N-terminal
region is necessary and the RR homology domain is dispensable
for RHIM-dependent interactions, the large RR region must be
retained for R1-mediated suppression of necroptosis.
We next investigated the potential for Casp8 interaction and
found the expected (Dufour et al., 2011a, 2011b) binding to
full-length ICP6 or ICP10 in HT-29 cells or 293T cells, an assay
where R1 homologs from MCMV and HCMV failed to bind (Fig-
ures 3E and S3B). When ICP6 and ICP10 mutants were evalu-
ated in stably transduced HT-29 cells, N-terminal deletions of
ICP10(D1–249) and ICP6(D1–243) as well as ICP6mutRHIMCell Host &bound Casp8, indicating that the N terminus was dispensable
and the RR homology domain mediated this interaction. ICP6-
mutRHIM behavior highlighted the RHIM independence of
Casp8 binding. The C-terminal truncation ICP6(1–1116) was
able to interact, but ICP6(1–1106), ICP6(1–835), and ICP6(1–
629) all failed to bind Casp8, indicating the importance of the
C-terminal 31 aa, particularly aa 1107–1116 (KTGMYYCKVR) in
this interaction (Figure 3E). This binding pattern correlated with
the ability to suppress necroptosis (Figure 3C). A triple amino
acid substitution mutant, ICP6(G865/867/870A), eliminating
enzymatic activity (Lembo and Brune, 2009), also disrupted
ICP6-Casp8 interaction (Figure 3E) and function (Figure 3C).
Thus, protein conformation necessary for nucleotide binding
may also sustain this interaction. Taken together, N-terminal
RHIM interactions with RIP1 and RIP3 and C-terminal interaction
with Casp8 are necessary for R1-mediated suppression of
necroptosis.
Relationship of Casp8 Binding to Suppression of
Necroptosis
Given that R1 interacts with RIP1, RIP3, and Casp8, we further
sought to interrogate contributions of the N-terminal RHIM
and C-terminal Casp8-binding domains as determinants of cell
fate. As expected, full-length ICP6 protected mock- or DICP6
virus-infected cells from T alone or T+S, and apoptosis
predominated in EV- or ICP6(1–629)-transduced cells, which
lack the Casp8 binding domain (Figures 4A–4D). In contrast,
ICP6mutRHIM effectively sensitized DICP6 virus-infected cells
to necroptosis (Figures 4B and 4D). Thus, ICP6 interaction with
Casp8 unleashed necroptosis. Consistent with the HSV-1 ICP6
mutants, RHIM-deficient HSV-2 ICP10(D1–249) increased sensi-
tivity to necroptosis induced by T or T+S treatment of DICP6-in-
fected cells (Figures S4C–S4G). When we employed the same
HSV-1 tetra-alanine ICP6 RHIM mutant virus as Huang et al.
(2015), necroptosis was induced in HSV-1mutRHIM-infected
cells treated with T alone (Figures 4E and 4F) but not in
parental F strain-infected cells. This pattern is the same as
ICP6mutRHIM-transduced cells infected with DICP6 virus (Fig-
ures 4A–4D, S4A, and S4B). Addition of RIP1 kinase inhibitor
GSK’963 or RIP3 kinase inhibitor GSK’840 reversed death (Fig-
ures S4A, S4B, and S4E). These data demonstrate that R1
RHIM prevents and the Casp8-binding domain sensitizes to
necroptosis. Furthermore, HSV-1mutRHIM virus replication
was inhibited under conditions where necroptosis was induced
(Figures 4G and 4H). In contrast to the growth defect of DICP6
virus (Figure 1C), HSV-1mutRHIM replication was not affected
by reduced RR activity. HSV-1mutRHIM replication was
compromised in the presence of T alone compared to parental
virus and was rescued by RIP1 or RIP3 kinase inhibitors, but
not by caspase inhibitor. Similarly, HSV-1mutRHIM plaque for-
mation was reduced by T alone andwas reversed by RIP1 kinase
inhibition (Figure S4H). Control treatment with antiviral com-
pound phosphonoformate inhibited mutant and parental viruses
to the same extent. Thus, the R1 RHIM prevented necroptosis
unleashed by R1 suppression of Casp8 activity. In summary,
TNFR1-induced necroptosis has the potential to cut short HSV
replication, but the pathway is blocked by a RHIM-specific
mechanism dependent on the N-terminal RHIM as well as a
separate C-terminal interaction with Casp8.Microbe 17, 243–251, February 11, 2015 ª2015 Elsevier Inc. 247
Figure 3. Contribution of RHIM and Casp8-Binding Domain of R1 to the Suppression of TNF-Induced Necroptosis
(A) The top panel depicts the amino acid sequence of RHIM-containing regions of human andmurine proteins RIP1, RIP3, TRIF, and DAI aligned with herpesvirus
R1 homologs, MCMV M45, HSV-1 ICP6, and HSV-2 ICP10. The position of the tetra-Ala mutation (mutRHIM) used to disrupt the RHIM-like motif of ICP6 and
ICP10, and used to define the RHIM in other proteins, is indicated below. The bottom panel is a schematic representation and summary of HSV-1 R1 mutant
proteins. Full-length (aa 1–1137) R1 is depicted at the top with an N-terminal (NH2) domain (white) with RHIM (black bar) and C-terminal RR homology domain
(gray) as well as the nucleotide binding GXGXXG motif (black circles). FLAG-tagged full-length ICP6mutRHIM, ICP6(D1–243) N-terminal deletion, and ICP6
N-terminal fragments (1–489, 1–629, 1–835, 1–1106, 1–1116), as well as RHIM mutant form ICP6(1–629, mutRHIM) and central fragment ICP6(244–629), are
depicted below.
(B) Viability of HT-29 cells stably transduced with EV, ICP6, ICP6(D1–243), ICP6mutRHIM, ICP6(1–489), ICP6(1–629), or ICP6(244–629), infected (mock, upper
panel; DICP6, lower panel), and treated with T+S+V from 2 to 24 hpi.
(C) Cell viability of HT-29 cells expressing ICP6(1–835), ICP6(1–1106), ICP6(1–1116), or ICP6(G865/867/870A) infected (mock, upper panel; DICP6, lower panel)
and treated with T+S+V from 2 to 24 hpi.
(D) IP/IB to detect FLAG-ICP6(1–629) or FLAG-ICP6(1–629,mutRHIM) interaction with Myc-RIP1 and Myc-RIP3. IP of cell lysates employed anti-Myc antibody
followed by IB with anti-Myc or anti-FLAG antibodies.
(E) IP/IB to detect R1 interaction with endogenous Casp8 in HT-29-ICP6, HT-29-ICP10, HT-29-M45, or HT-29 cells expressing FLAG-tagged mutants of ICP6
(D1–243, 1–629, 1–835, 1–1106, 1–1116, G865/867/870A, and mutRHIM) or ICP10(D1–249). IP of cell lysates was with anti-FLAG antibody followed by IB with
anti-Casp8 or anti-FLAG antibodies. Protein molecular size is shown to the right of the lanes. Data with error bars depict mean ± SD; *p < 0.05, **p < 0.01, ***p <
0.001. See also Figure S3.
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Figure 4. C-Terminal Interaction of R1 with
Casp8 Sensitizes Cells to Necroptosis
(A and B) Viability of HT-29-EV, HT-29-ICP6,
HT-29-ICP6mutRHIM, and HT-29-ICP6(1–629)
cells that were either mock-infected or infected
with DICP6 or KOS virus (MOI = 5) and treated with
T or T+S from 2 to 24 hpi.
(C and D) IB of p-MLKL, Cl-Casp3, b-actin, and
FLAG-tagged ICP6 species in HT-29 cells stably
expressing EV, ICP6, ICP6mutRHIM, and ICP6(1–
629). Cells were either mock-infected or infected
with KOS orDICP6 virus (MOI = 5) and then treated
with T from 2 to 15 hpi or T+S from 2 to 10 hpi.
(E) Viability of HSV-1 parental strain F or RHIM
mutant virus-infected HT-29 cells (MOI = 10), or
mock-infected, and treated from 1 to 24 hpi with T,
T+V, T+GSK’963, or T+GSK’840.
(F) IB to detect cleaved p-MLKL, Cl-Casp3, and
b-actin in HT-29 cells infected with HSV-1 (F strain)
or HSV-1mutRHIM (MOI = 1.5), or mock-infected,
and then treated with T from 1 to 20 hpi.
(G and H) Replication levels of HSV-1 and HSV-
1mutRHIM virus in HT-29 cells (MOI = 5) in DMSO
control medium or in medium containing T, T+V, or
T+V in the presence or absence of RIP1 kinase
inhibitor GSK’963 (1 mM) or RIP3 kinase inhibitor
GSK’840 (3 mM) as shown. Viral titers were deter-
mined by plaque assay on Vero cells at the indi-
cated time (hpi). Data with error bars depict mean ±
SD; *p < 0.05, **p < 0.01, ***p < 0.001. See also
Figure S4.DISCUSSION
Pathogenesis of herpesviruses, like other large DNA viruses, re-
lies on a broad array of viral gene products that modulate PCD
(Galluzzi et al., 2008; Mocarski et al., 2012). Consistent with pre-
vious evaluations (Galvan and Roizman, 1998; Leopardi et al.,
1997), WT HSV-1 resists, but R1 mutant HSV-1 exhibits sensi-
tivity to TNFR1 death pathways, extending the importance of
alternate necrotic and apoptotic outcomes in human cells. Al-
phaherpesvirus R1 homologs are long-recognized components
of a virus-encoded RR enzyme necessary to scavenge deoxynu-
cleotides. As revealed during investigations of TNFR1-, TLR3-,
and MCMV M45mutRHIM-associated PCD pathways, cultured
cells vary in susceptibility to necroptosis even though the
pathway remains intact in mice (Upton et al., 2010, 2012). HT-Cell Host & Microbe 17, 243–251,29 (He et al., 2009) and U937 (Temkin
et al., 2006) human cells preserve the
necessary machinery to support necrop-
tosis and share the ability to support
HSV R1-mediated suppression of this
pathway. The N terminus of HSV-1 or
HSV-2 R1 contains a RHIM that blocks
the interaction of RIP1 and RIP3 in a
mechanism that is reminiscent of vIRA
(Kaiser et al., 2013a; Upton et al., 2010,
2012). Indeed, as predicted (Lembo and
Brune, 2009), a RHIM competitor strategy
is common to three herpesviruses: HSV-
1, HSV-2, and MCMV. The need to triggerdeath receptor activation to observe an impact of HSV R1 con-
trasts MCMV, where mutant virus directly activates DAI-RIP3
necroptosis in a pattern that is independent of TNFR1 as well
as RIP1 (Upton et al., 2010, 2012).
Necroptosis emerged as an alternate pathway potentially un-
leashed by vaccinia-encoded caspase suppressors (Chan et al.,
2003; Cho et al., 2009). Although MCMV encodes a Casp8-spe-
cific inhibitor, vICA, with clear potential to unleash necroptosis
(Kaiser et al., 2011), our present study reveals the core impor-
tance of Casp8 inhibition in triggering necroptosis during viral
infection. Interestingly, with HSV, inhibition of Casp8 and RIP3
activation are properties of a single viral gene product. HSV R1
inhibits Casp8 by targeting the death effector domain, similar
to a viral FLIP (Dufour et al., 2011b). In HSV-1 and HSV-2,
this activity suppresses apoptosis and switches outcome toFebruary 11, 2015 ª2015 Elsevier Inc. 249
necroptosis. Even though the replication of HSV is much more
rapid than MCMV, the combined activities of the N-terminal
RHIM and the C-terminal RR domains maintain cell viability
that promotes efficient viral replication. It is significant that
similar interlaced host defense pathways described in mice
(Upton et al., 2010, 2012) play out in human cells and can be pre-
dicted to impact viral pathogenesis. This balance of Casp8 activ-
ity is reminiscent of the relationship between Casp8 and RIP3
death pathways during mammalian development (Kaiser et al.,
2011), where the potent ability of necroptosis to undermine tis-
sue homeostasis and drive inflammatory disease was described
(Kaiser et al., 2013b). This delicate balance contributes to innate
antiviral immunity in humans.
Recently, ICP6 and ICP10 have been shown to trigger RIP3-
dependent necroptosis in mouse cells, where both appear to
promote RHIM signaling (Huang et al., 2015; Wang et al.,
2014). The significance of necroptosis as a species barrier
does not extend to MCMV, given that vIRA prevents necroptosis
in mouse or human cells. From the limited information at hand,
viral inhibitors of necroptosis most likely evolved to disrupt
RHIM-dependent signaling rather than to promote it (Kaiser
et al., 2013b). Natural human pathogens HSV-1 and HSV-2
add significantly to our understanding of species specificity of
RHIM signaling leading to alternate necroptotic and apoptotic
outcomes.
EXPERIMENTAL PROCEDURES
Cell Viability Assays
Viability assays were performed 16–18 hr after seeding cells. Infections with
HSV-1 (MOI = 5 or 10) were in 100 ml of medium for 1–2 hr, at which time treat-
ment with T, V, and/or S or S7 (or DMSO at 0.1% as control) was initiated. Cell
viability was determined on 96-well plates by measuring intracellular levels of
ATP using the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega) on
a Synergy HT Multi-Detection microplate reader (Bio-Tek). Alternatively, cells
on 48-well plates were cultured in medium containing 62.5 nM SYTOX Green
(Invitrogen), a live-cell impermeant nucleic acid fluorescent dye, and assessed
using an IncuCyte system (Essen Biosystems). Dead cells per mm2 were
calculated from four images at indicated time points. Mean ± SD of triplicates
was determined using Student’s t test (GraphPad Prism). All experiments were
repeated at least three times with similar results.
Immunoprecipitation and Immunoblot Analysis
IP and IB analyses were performed as described previously (Kaiser et al.,
2008), modified such that clarified cell lysates were incubated overnight with
rabbit anti-c-Myc agarose conjugate (Sigma-Aldrich) and protein A/G agarose
(Santa Cruz) for IP analyses, then washed 4–6 times. Samples were separated
on denaturing SDS-PAGE in a 10%gel and then electrophoretically transferred
to Immobilon PVDF membranes (Millipore). Antibodies for IB analysis were:
mouse anti-b-actin (AC-74; Sigma), mouse anti-RIP1 (clone 38; BD
Biosciences), rabbit anti-RIP3 (Abcam), rabbit anti-phospho-S358 MLKL
(ab187091, Abcam), mouse anti-FLAG and HRP conjugate (Sigma-Aldrich),
mouse anti-c-FLIP (NF6; Alexis), rabbit anti-cIAP1 (H-83) and rabbit anti-
cIAP2 (H-85, Santa Cruz), mouse anti-His (70794, Novagen), mouse anti-
Casp8 (5F7, Enzo), rabbit anti-Cl-Casp3 (Cell Signaling), anti-mouse IgG-
HRP and anti-rabbit IgG-HRP conjugate (Vector Laboratories), human immune
globulin (CSL Behring), and goat anti-human IgG-HRP conjugate (Millipore).
For further details, see the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chom.2015.01.003.250 Cell Host & Microbe 17, 243–251, February 11, 2015 ª2015 ElseAUTHOR CONTRIBUTIONS
H.G. and S.O. performed experiments. P.A.H., J.N.F., P.J.G., and J.B. charac-
terized RIP1 and RIP3 kinase inhibitors and S166 phospho-RIP1 antibody.
E.S.M. and W.J.K. designed and managed the project and, with H.G., assem-
bled figures and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Dr. Sandra K. Weller for HSV-1 KOS and DICP6 viruses, Dr. Jiahuai
Han for HSV-1 F and HSV-1mutRHIM viruses, Dr. Yves Langelier for plasmids,
and Dr. Domogoj Vucic (Genentech) for BV6. Linda Roback and Chunzi Huang
provided technical assistance. Support was from NIH (PHS grants R01
AI020211 and R01 GM112547 to E.S.M. and DP1 OD012198 to W.J.K.),
although the content is solely the responsibility of the authors and not the
NIH or PHS. H.G., W.J.K. and E.S.M. declare no competing financial interests.
S.O. is an employee of Shionogi Pharmaceuticals. P.A.H., J.N.F., P.J.G., and
J.B. are employees of GlaxoSmithKline.
Received: June 27, 2014
Revised: November 8, 2014
Accepted: January 9, 2015
Published: February 11, 2015
REFERENCES
Berger, A.K., and Danthi, P. (2013). Reovirus activates a caspase-independent
cell death pathway. MBio. 4, e00178–00113.
Bousfiha, A., Picard, C., Boisson-Dupuis, S., Zhang, S.Y., Bustamante, J.,
Puel, A., Jouanguy, E., Ailal, F., El-Baghdadi, J., Abel, L., and Casanova,
J.L. (2010). Primary immunodeficiencies of protective immunity to primary in-
fections. Clin. Immunol. 135, 204–209.
Brune, W., Me´nard, C., Heesemann, J., and Koszinowski, U.H. (2001). A ribo-
nucleotide reductase homolog of cytomegalovirus and endothelial cell
tropism. Science 291, 303–305.
Chabaud, S., Sasseville, A.M., Elahi, S.M., Caron, A., Dufour, F., Massie, B.,
and Langelier, Y. (2007). The ribonucleotide reductase domain of the R1 sub-
unit of herpes simplex virus type 2 ribonucleotide reductase is essential for R1
antiapoptotic function. J. Gen. Virol. 88, 384–394.
Chan, F.K., Shisler, J., Bixby, J.G., Felices, M., Zheng, L., Appel, M., Orenstein,
J., Moss, B., and Lenardo, M.J. (2003). A role for tumor necrosis factor recep-
tor-2 and receptor-interacting protein in programmed necrosis and antiviral re-
sponses. J. Biol. Chem. 278, 51613–51621.
Cho, Y.S., Challa, S., Moquin, D., Genga, R., Ray, T.D., Guildford, M., and
Chan, F.K. (2009). Phosphorylation-driven assembly of the RIP1-RIP3 com-
plex regulates programmed necrosis and virus-induced inflammation. Cell
137, 1112–1123.
Dufour, F., Bertrand, L., Pearson, A., Grandvaux, N., and Langelier, Y. (2011a).
The ribonucleotide reductase R1 subunits of herpes simplex virus 1 and 2 pro-
tect cells against poly(I $ C)-induced apoptosis. J. Virol. 85, 8689–8701.
Dufour, F., Sasseville, A.M., Chabaud, S., Massie, B., Siegel, R.M., and
Langelier, Y. (2011b). The ribonucleotide reductase R1 subunits of herpes sim-
plex virus types 1 and 2 protect cells against TNFalpha- and FasL-induced
apoptosis by interacting with caspase-8. Apoptosis 16, 256–271.
Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D.P., Langlais, C., Hupe,
M., Cain, K., MacFarlane, M., Ha¨cker, G., and Leverkus, M. (2011). cIAPs block
Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death
complex differentially regulated by cFLIP isoforms. Mol. Cell 43, 449–463.
Fliss, P.M., Jowers, T.P., Brinkmann, M.M., Holstermann, B., Mack, C.,
Dickinson, P., Hohenberg, H., Ghazal, P., and Brune, W. (2012). Viral mediated
redirection of NEMO/IKKg to autophagosomes curtails the inflammatory
cascade. PLoS Pathog. 8, e1002517.
Galluzzi, L., Brenner, C., Morselli, E., Touat, Z., and Kroemer, G. (2008). Viral
control of mitochondrial apoptosis. PLoS Pathog. 4, e1000018.
Galvan, V., and Roizman, B. (1998). Herpes simplex virus 1 induces and blocks
apoptosis at multiple steps during infection and protects cells from exogenousvier Inc.
inducers in a cell-type-dependent manner. Proc. Natl. Acad. Sci. USA 95,
3931–3936.
Goldstein, D.J., and Weller, S.K. (1988). Herpes simplex virus type 1-induced
ribonucleotide reductase activity is dispensable for virus growth and DNA syn-
thesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol.
62, 196–205.
He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., and Wang, X. (2009).
Receptor interacting protein kinase-3 determines cellular necrotic response
to TNF-alpha. Cell 137, 1100–1111.
Huang, Z., Wu, S.-Q., Liang, Y., Zhou, X., Chen, W., Li, L., Wu, J., Zhuang, Q.,
Chen, C., Li, J., et al. (2015). RIP1/RIP3 Binding to HSV-1 ICP6 Initiates
Necroptosis to Restrict Virus Propagation in Mice. Cell Host Microbe 17, this
issue, 229–242.
Kaiser, W.J., Upton, J.W., and Mocarski, E.S. (2008). Receptor-interacting
protein homotypic interaction motif-dependent control of NF-kappa B activa-
tion via the DNA-dependent activator of IFN regulatory factors. J. Immunol.
181, 6427–6434.
Kaiser, W.J., Upton, J.W., Long, A.B., Livingston-Rosanoff, D., Daley-Bauer,
L.P., Hakem, R., Caspary, T., and Mocarski, E.S. (2011). RIP3 mediates the
embryonic lethality of caspase-8-deficient mice. Nature 471, 368–372.
Kaiser, W.J., Sridharan, H., Huang, C., Mandal, P., Upton, J.W., Gough, P.J.,
Sehon, C.A., Marquis, R.W., Bertin, J., and Mocarski, E.S. (2013a). Toll-like
receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288,
31268–31279.
Kaiser, W.J., Upton, J.W., and Mocarski, E.S. (2013b). Viral modulation of pro-
grammed necrosis. Curr Opin Virol 3, 296–306.
Kaiser, W.J., Daley-Bauer, L.P., Thapa, R.J., Mandal, P., Berger, S.B., Huang,
C., Sundararajan, A., Guo, H., Roback, L., Speck, S.H., et al. (2014). RIP1 sup-
presses innate immune necrotic as well as apoptotic cell death during
mammalian parturition. Proc. Natl. Acad. Sci. USA 111, 7753–7758.
Krause, E., de Graaf, M., Fliss, P.M., Do¨lken, L., and Brune, W. (2014). Murine
cytomegalovirus virion-associated protein M45 mediates rapid NF-kB activa-
tion after infection. J. Virol. 88, 9963–9975.
Lembo, D., and Brune, W. (2009). Tinkering with a viral ribonucleotide reduc-
tase. Trends Biochem. Sci. 34, 25–32.
Lembo, D., Donalisio, M., Hofer, A., Cornaglia, M., Brune, W., Koszinowski, U.,
Thelander, L., and Landolfo, S. (2004). The ribonucleotide reductase R1 homo-
log of murine cytomegalovirus is not a functional enzyme subunit but is
required for pathogenesis. J. Virol. 78, 4278–4288.
Leopardi, R., Van Sant, C., and Roizman, B. (1997). The herpes simplex virus 1
protein kinase US3 is required for protection from apoptosis induced by the
virus. Proc. Natl. Acad. Sci. USA 94, 7891–7896.
Lundberg, P., Welander, P.V., Edwards, C.K., 3rd, van Rooijen, N., and Cantin,
E. (2007). Tumor necrosis factor (TNF) protects resistant C57BL/6mice against
herpes simplex virus-induced encephalitis independently of signaling via TNF
receptor 1 or 2. J. Virol. 81, 1451–1460.
Mandal, P., Berger, S.B., Pillay, S., Moriwaki, K., Huang, C., Guo, H., Lich, J.D.,
Finger, J., Kasparcova, V., Votta, B., et al. (2014). RIP3 induces apoptosis
independent of pronecrotic kinase activity. Mol. Cell 56, 481–495.
McCormick, A.L., and Mocarski, E.S. (2013). Cell death pathways controlled
by cytomegaloviruses. In Cytomegaloviruses: From Molecular Pathogenesis
to Intervention, M.J. Reddehase, ed. (Norfolk, United Kingdom: Caister
Scientific Press), pp. 263–276.Cell Host &Mocarski, E.S., Upton, J.W., and Kaiser, W.J. (2012). Viral infection and the
evolution of caspase 8-regulated apoptotic and necrotic death pathways.
Nat. Rev. Immunol. 12, 79–88.
Mocarski, E.S., Kaiser, W.J., Livingston-Rosanoff, D., Upton, J.W., and Daley-
Bauer, L.P. (2014). True grit: programmed necrosis in antiviral host defense,
inflammation, and immunogenicity. J. Immunol. 192, 2019–2026.
Newton, K., Dugger, D.L., Wickliffe, K.E., Kapoor, N., de Almagro, M.C., Vucic,
D., Komuves, L., Ferrando, R.E., French, D.M., Webster, J., et al. (2014).
Activity of protein kinase RIPK3 determines whether cells die by necroptosis
or apoptosis. Science 343, 1357–1360.
Sergerie, Y., Rivest, S., and Boivin, G. (2007). Tumor necrosis factor-alpha and
interleukin-1 beta play a critical role in the resistance against lethal herpes sim-
plex virus encephalitis. J. Infect. Dis. 196, 853–860.
Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu,
W., Lei, X., andWang, X. (2012). Mixed lineage kinase domain-like protein me-
diates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227.
Temkin, V., Huang, Q., Liu, H., Osada, H., and Pope, R.M. (2006). Inhibition of
ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol.
Cell. Biol. 26, 2215–2225.
Upton, J.W., and Chan, F.K. (2014). Staying alive: cell death in antiviral immu-
nity. Mol. Cell 54, 273–280.
Upton, J.W., Kaiser, W.J., and Mocarski, E.S. (2008). Cytomegalovirus M45
cell death suppression requires receptor-interacting protein (RIP) homotypic
interaction motif (RHIM)-dependent interaction with RIP1. J. Biol. Chem.
283, 16966–16970.
Upton, J.W., Kaiser, W.J., and Mocarski, E.S. (2010). Virus inhibition of RIP3-
dependent necrosis. Cell Host Microbe 7, 302–313.
Upton, J.W., Kaiser, W.J., and Mocarski, E.S. (2012). DAI/ZBP1/DLM-1 com-
plexes with RIP3 to mediate virus-induced programmed necrosis that is tar-
geted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290–297.
Vandenabeele, P., Declercq, W., Van Herreweghe, F., and Vanden Berghe, T.
(2010). The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci.
Signal. 3, re4.
Varfolomeev, E., Blankenship, J.W., Wayson, S.M., Fedorova, A.V., Kayagaki,
N., Garg, P., Zobel, K., Dynek, J.N., Elliott, L.O., Wallweber, H.J., et al. (2007).
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation,
and TNFalpha-dependent apoptosis. Cell 131, 669–681.
Wang, X., Li, Y., Liu, S., Yu, X., Li, L., Shi, C., He, W., Li, J., Xu, L., Hu, Z., et al.
(2014). Direct activation of RIP3/MLKL-dependent necrosis by herpes simplex
virus 1 (HSV-1) protein ICP6 triggers host antiviral defense. Proc. Natl. Acad.
Sci. USA 111, 15438–15443.
Weng, D., Marty-Roix, R., Ganesan, S., Proulx, M.K., Vladimer, G.I., Kaiser,
W.J., Mocarski, E.S., Pouliot, K., Chan, F.K., Kelliher, M.A., et al. (2014).
Caspase-8 and RIP kinases regulate bacteria-induced innate immune re-
sponses and cell death. Proc. Natl. Acad. Sci. USA 111, 7391–7396.
Zhang, S.Y., Herman, M., Ciancanelli, M.J., Pe´rez de Diego, R., Sancho-
Shimizu, V., Abel, L., and Casanova, J.L. (2013). TLR3 immunity to infection
in mice and humans. Curr. Opin. Immunol. 25, 19–33.
Zhao, J., Jitkaew, S., Cai, Z., Choksi, S., Li, Q., Luo, J., and Liu, Z.G. (2012).
Mixed lineage kinase domain-like is a key receptor interacting protein 3 down-
stream component of TNF-induced necrosis. Proc. Natl. Acad. Sci. USA 109,
5322–5327.Microbe 17, 243–251, February 11, 2015 ª2015 Elsevier Inc. 251
